Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
What happened
The Food and Drug Administration (FDA) is classifying the Spinal Muscular Atrophy newborn screening test system into class II (special controls). This action, signed by Donald Trump, allows the device to be regulated with "special controls" in addition to general controls, rather than the higher-risk class III. The classification was applicable on November 9, 2022, and this order is effective June 11, 2026.
Why it matters
This reclassification aims to ensure the device's safety and effectiveness while reducing regulatory hurdles. By lowering the classification, the FDA believes it will enhance patients' access to beneficial innovative medical devices.
Who it affects
- ›Newborns screened for Spinal Muscular Atrophy
- ›Parents of newborns
- ›Medical device manufacturers
- ›Healthcare providers
- ›FDA regulatory processes
The receipts are official. The summary is ours.
Read on Federal Register ↗Summaries are generated from the official text and may simplify or omit nuance. The official document is the source of truth.